|
?:authorAffiliation
|
-
[\'Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. Electronic address: douglas.puricelliperin@nih.gov.\', \'Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Regional Cancer Center of Stockholm Gotland, Stockholm, Sweden.\', \'Center for Primary Care and Public Health (unisanté), University of Lausanne, Lausanne, Switzerland.\', \'Epidemiology and Evaluation Department, Hospital del Mar, Barcelona, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain; REDISSEC (Health Services Research on Chronic Patients Network), Madrid, Spain.\', \'Usher Institute, University of Edinburgh, Scotland, UK.\', \'Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel; Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Clalit National Cancer Control Center, Haifa, Israel.\', \'SSD Epidemiologia e screening - CPO, University Hospital \'Città della Salute e della Scienza\', Turin, Italy.\', \'Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA.\', \'Prevention and Cancer Control, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.\', \'Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA.\', \'American Cancer Society, Atlanta, GA, USA.\', \'Radboud university medical center, Radboud Institute for Health Sciences, Nijmegen, the Netherlands; Dutch Expert Centre for Screening, Nijmegen, the Netherlands.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}